IRIS
CONSOLARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.332
Totale 12.332
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 12.332
Totale 12.332
Salva come PNG Salva come JPEG
Città #
Genova 8.887
Rapallo 1.366
Genoa 1.059
Vado Ligure 989
Bordighera 31
Totale 12.332
Salva come PNG Salva come JPEG
Nome #
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 159
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 158
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 149
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 149
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 140
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 136
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 135
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 134
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 132
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 131
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 128
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 127
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 124
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 123
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 121
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 121
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 121
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 121
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 120
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 120
Advances in biomarkers for paediatric rheumatic diseases 120
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 118
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 117
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 117
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 116
Clinical outcome measures in juvenile idiopathic arthritis 116
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 114
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 114
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 114
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 114
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 113
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 112
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
Glucocorticoids in juvenile idiopathic arthritis. 111
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 111
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 111
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 110
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 110
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 106
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 105
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 105
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 104
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
Prevalence of overweight and obesity in 2- to 6-year-old Italian children 103
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
Recent therapeutic advances in juvenile idiopathic arthritis 102
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 102
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis 99
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 99
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. 96
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 96
A child with a novel ACAN missense variant mimicking a septic arthritis 96
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). 95
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. 94
Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? 93
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 93
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 91
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 90
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 89
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 87
Optimisation of disease assessments in juvenile idiopathic arthritis. 86
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 86
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 86
Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. 85
Defining criteria for disease activity states in juvenile idiopathic arthritis 83
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force 83
Glucocorticoids in paediatric rheumatology 81
Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children 81
Totale 10.944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.148
article - articoli 43.148
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.757 0 0 0 0 309 588 719 594 513 567 340 127
2020/20211.389 68 157 71 150 76 70 137 135 71 178 70 206
2021/20221.488 72 59 122 119 55 123 61 326 125 175 63 188
2022/20231.632 147 147 21 144 251 274 9 159 276 14 165 25
2023/2024822 35 113 35 110 71 73 89 46 41 35 48 126
2024/20251.028 78 217 111 208 414 0 0 0 0 0 0 0
Totale 12.839